Maryana Salamah, Youssef Alahmad
Maryana Salamah1, Youssef Alahmad1,2
1Department of Pharmaceutical Chemistry and Drug Quality Control, Faculty of Pharmacy, Al-Baath University, Homs, Syria.
2Department of Pharmaceutical Chemistry and Drug Quality Control, Faculty of Pharmacy, Arab University for Science and Technology, Hama, Syria.
Volume - 13,
Issue - 4,
Year - 2020
There are several generics of Amlodipine besylate tablets locally manufactured by some Syrian pharmaceutical companies. this study tries to evaluate the pharmaceutical and chemical equivalence of amlodipine besylate tablets from 5 Syrian pharmaceuticals and comparison the results with an innovator (Norvasc®). The pharmaceutical equivalence and the quality for each generic were assessed through the evaluation of standard tests such as uniformity of weight, friability, hardness, disintegration, content uniformity, uniformity of dosage units and dissolution rate. The assay was conducted by using HPLC (the analytical column was C 18, 150 x 4.6 mm I.D, 4µm particle size, the mobile phase was a mixture of 30% acetonitrile and 70% 100 mM ammonium acetate pH 5 with flow rate of 1ml/min and UV detection at 237 nm for amlodipine). All the generics complied with the standard specifications for uniformity of weight (<±7.5%), friability (<1%), content uniformity (85-115%), uniformity of dosage units (<15), hardness and disintegration tests. The chromatographic system found to be suitable for quantitative determination of amlodipine (the resolution was 13.587, theoretical plates were 7080, tailing factor was 1.921, RSD% was 1.087). The result of assay indicated that only (B, C, E) showed values out of the range specified in the USP (90-110%) but all products released more than 75% of the labeled quantity during 30 minutes. Only product D had similarity factor (f2) >50. This confirms the need for continuous monitoring of the safety, quality and efficacy of the marketed generic drugs with a view to bioequivalence and agreement with pharmacopoeia standards.
Cite this article:
Maryana Salamah, Youssef Alahmad. Assessment and Comparison of Pharmaceutical Equivalence of Amlodipine Besylate Tablets Available in Syria under Biowaiver Conditions. Research J. Pharm. and Tech. 2020; 13(4):1720-1724. doi: 10.5958/0974-360X.2020.00310.8
1. Al-Jazairi A. S. et al. Brand and generic medications: Are they interchangeable. Annals of Saudi Medicine. 2008; 28(1): 33-41.
2. Kohler J.C. et al., An examination of pharmaceutical systems in severely disrupted countries. BMC International Health and Human Rights. 2012; 12(34): 1-11.
3. Pavignani E et al., Making sense of apparent chaos: health-care provision in six country case studies. International Review of the Red Cross. 2013; 95(889): 41–60.
4. Dharmalingam SR.et al., Comparative quality control evaluation of atenolol tablet marketed in Kualalampur, Malaysia. British Journal of Pharmaceutical Research. 2014; 4 (13): 1688-1695.
5. Shohin, I.E. et al., Application of scientifically justified biowaiver for immediate release solid oral dosage form containing BCS class iii drug (Atenolol). International Journal of Pharmaceutical science. 2011; 3 (1): 918-923
6. Allam A, EL Gamal S. S. and Naggar V. F., Bioavailability: A Pharmaceutical Review. International Journal of Novel Drug Delivery Technology. 2011; 1 (1): 77-93.
7. FDA Guidance for Industry, 2017 Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, available at: https://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf.
8. Feroz M et al., Assessment of Pharmaceutical Quality Control and Equivalence of Various Brands of Amlodipine Besylate (5 Mg) Tablets Available in The Pakistani Market Under Biowaiver Conditions. International Journal of Pharmacy and Pharmaceutical Sciences. 2014; 6 (2): 909-913.
9. Beale J. M and Block J. H., Wilson and Gisvold’s textbook of organic medicinal and pharmaceutical chemistry. Lippincott Williams & Wilkins, a Wolters Kluwer Business, Philadelphia, 2011.
10. Narmada G.Y. et al., Formulation, Evaluation and Optimization of Fast Dissolving Tablets Containing Amlodipine Besylate by Sublimation Method. ARS Pharmaceutical. 2009; 50(3): 129-144.
11. Joshi M, Rao B.S. and Khan G.M., Study of Drug Use in Essential Hypertension and their Compliance. Kathmandu University Journal of Science Engineering and Technology. 2006; 2(1): 1-13.
12. Arrunátegui L. B. et al., Biopharmaceutics classification system: importance and inclusion in biowaiver guidance. Brazilian Journal of Pharmaceutical Sciences. 2015; 51(1): 143-154.
13. Chi-Yuan Wu and Benet L.Z., Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System. Pharmaceutical Research. 2005; 22(1): 11-23.
14. European Pharmacopeia, 7th edition
15. British Pharmacopoeia. 2013.
16. United States Pharmacopeia, USP34-NF29.
17. De Borba B and Rohrer J, Development of an Assay for Besylate in Amlodipine Besylate by IC and a Second Assay to Simultaneously Determine Amlodipine and Besylate by HPLC. Thermo Fisher Scientific. 2016; 1-7.
18. Chabukswar A.R. et al., HPLC Method Development for Telmisartan and Amlodipine. Research J. Pharm. and Tech. 2010; 3(4): 1227-1230.
19. Shah J. C. and Deshpande A, Kinetic modeling and comparison of in vitro dissolution profiles. World Journal of Pharmaceutical Sciences. vol. 2014; 2(4): 302-309.
20. Gonjari I.D., Karmarkar A. B. and Hosmani A. H., Evaluation of in Vitro Dissolution Profile Comparison Methods of Sustained Release Tramadol Hydrochloride Liquisolid Compact Formulations with Marketed Sustained Release Tablets. Digest Journal of Nanomaterials and Biostructures. 2009; 4(4): 651-661.